| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1470af2d007afa44390c8c9cfbaff5f1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3015 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2014-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c201e74e14cecb3808a14af70b1952af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ac448cde3092c7320b13a7dc4bdfe5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_798e67f75a5affb021aabc8541b13fc5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d56507ddec81b986516a8daf05f18a13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e194e6cf19d02c00a91bb94444d071c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c381be66e1d5d3015758fce9b427de31 |
| publicationDate |
2015-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201536809-A |
| titleOfInvention |
Method for inhibiting cancer by inhibiting TMCC3 |
| abstract |
An antibody or binding fragment thereof directed against transmembrane coiled-coil region protein 3 (TMCC3), including the CDR sequences set forth in the specification. A method of treating cancer comprising administering to a subject in need thereof an antibody against transmembrane coiled-coil region protein 3 (TMCC3). This antibody binds to the epitope of the TMCC3 intercoil domain. A method of diagnosing or evaluating a cancer condition comprising assessing the amount or activity of transmembrane coiled-coil region protein 3 (TMCC3) in a sample, wherein an increase in the amount or activity of the TMCC3 is expressed in comparison to a standard There is the presence of cancer stem cells in this sample. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I631958-B |
| priorityDate |
2013-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |